1 Inspiring Day, 16 Speakers From The Pharmaceutical Industry, Patient Advocacy Groups & Patients Themselves Share Their Insights Into Levelling Up Clinical Trials In Pharma!
Advances In Patient Recruitment, Engagement & Participation To Harness New Opportunities For Trial Design Innovation & Decentralisation For Patient-Led, Value-Adding Clinical Trials In Pharma
Harness The Patient’s Voice Throughout Clinical Design & Operations & Implement Their Insights To Improve Patient Recruitment, Retention & Trial Viability – Employ The Latest Data & Tech Advances To Power Decentralised Trials & Effective Evidence Gathering – Collaborate Effectively With Stakeholders To Ensure Regulatory Approval & Boost Speed To-Market!
A One-Day, Brand-Led Conference & Networking Event, 15th September 2022, Central London, The Millennium Gloucester Hotel.
08.30 Registration, Informal Networking & GIC Opening Remarks
09.00 Morning Chair’s Opening Remarks
DECENTRALISED TRIAL SUCCESS - DOUBLE PERSPECTIVE
09.10 Leverage Opportunities For Decentralised Clinical Trials With Stringent Patient Strategies Which Boost Trial Success & Harmonise With Increased International Co-Operation
• Covid-19 has presented the opportunity for decentralised trials, but how can we ensure these still fit regulatory approval for the future?
• How can patients be identified remotely to increase the patient pool available for trials?
• What innovative knowledge-sharing strategies can be implemented to accelerate trial feasibility in previously unrepresented regions and countries?
• Decentralised trials don’t fit with all therapy areas, so how can we ensure that the right trial design is in place to make decentralised trials as effective as possible?
• Remote but not removed? How can we still ensure high levels of patient care and support during decentralised trials?
9:10 Cristina De Juan, Innovation Lead, Global Clinical Sciences & Operations, UCB
PATIENT RETENTION & ENGAGEMENT - Q&A PANEL
09:50 Build Deeper Relationships With Patients & Understand Their Needs To Reduce Drop-Off Rates & Power Evidence Viability
• It starts from the very beginning! How can patients be embedded at in trial design phase and their insights harnessed to increase retention?
• Develop deeper relationships with advocacy groups and harness their insights to develop trials that truly fit patients’ needs
• How can information be presented to patients to ensure they can make informed decisions, without overloading them with paperwork?
• Patient retention is even more crucial in rare diseases, so how can retention strategies be adapted to work even more effectively for trials in key therapy areas?
Alex Sparrowhawk, Chairman, UK CAB
Mark Doyle, Director, A Life In A Day
10.20 Morning Refreshment Break With Informal Networking
PROACTIVE PATIENT RECRUITMENT - KEY UPDATES
10:50 Overcome Barriers To Greater Patient Enrolment & Remove Pain Points To Boost Trial Success
• Create clear, informative patient engagement and recruitment communications which actively ease patient concerns to boost patient
recruitment
• Which channels and communications methods are most impactful in making patients and HCPs aware of forthcoming trials?
• How can existing relationships with advocacy groups and patients create a long-term pipeline of informed patients willing to take part in trials?
• Deliver clinical trial patient materials in digestible language to ensure patient understanding and informed consent and increase trial recruitment
11:10 Bonus Session; Patient and Public Involvement in Research
• How to perform this properly in your organisation
• Exploring the impact this plays in efficient timeline and budget planning
Keith Berelowitz, Director of Operations, Richmond Pharmacology
PATIENT-CENTRIC TRIAL DESIGN - DOUBLE PERSPECTIVE
11:40 Engage & Embed Patients Early In The Trial Design Process For Patient-Focused Trials Which Boost Participation & Retention
• Effectively collaborate with patients throughout trial designs to avoid common pitfalls and pain points that disincentivise patient involvement in clinical trials
• How can patient-centric trials be embedded throughout an organisation, and end the days of piecemeal engagement?
• Are you collecting the evidence that’s important to patients? How can trial outcomes be designed with patient’s input to collect the results that deliver greater outcomes for patients and the business?
• It’s easier said than done! How can internal barriers to patient-designed trial be overcome and the value of their input be showcased to stakeholders?
11:40 Marta Garcia Manrique, Chief Patient Officer, R&D, Servier
12:00 Oleks Gorbenko, Global Patient Centricity Director, Ipsen
A PATIENT’S PERSPECTIVE
12:20 Hear A Patient’s Perspective Directly On Their Experiences Of Engagement With Clinical Trials & Harnessing Patient-Centric Design To Boost Recruitment & Retention
Olive Fulton, Patient Advocate
12:40 Lunch For Delegates, Speakers & Partners
13:10 Informal Peer-To-Peer Discussions
A) Digital Transformation
Francesco Butti, Local Clinical Operations & Budget Head, Novartis
B) Combatting Misinformation
C) Informed Consent
D) Global Disruption
E) Rare Diseases
F) Remuneration
13:40 Afternoon Chair’s Opening Remarks
Domenico Merante, Global Clinical Development TA Lead Nephrology & Orphan Disease, Vifor Pharma Area
PATIENT PERSPECTIVES - Q&A PANEL
13:50 Hear Directly From Patients & Advocates: What Are Drivers & Barriers To Participation? Honest Feedback About Key Innovations & Patient-Centric Approaches To Boost Patient Experiences, Recruitment & Retention In Clinical Trials
• What key drivers and motivators inspire you to take part in a clinical trial – and what are your top three barriers to participation?
• What key logistical pain points can trial designers focus on to make patient participation in trials as smooth as possible?
• How can pharma do more to hear the patient voice throughout the entirety of the clinical trial process?
• How can digital advances improve patient trial experiences, whilst still maintaining the human touch when needed?
Marko Korenjak, President, ELPA
Olive Fulton, Patient Advocate
14:20 Bonus Session; Reserved For Exclusive Conference Partner
PROACTIVE PATIENT RECRUITMENT -KEY UPDATES
14:50 Overcome Barriers To Greater Patient Enrolment & Remove Pain Points To Boost Trial Success
• Create clear, informative patient engagement and recruitment communications which actively ease patient concerns to boost patient recruitment
• Which channels and communications methods are most impactful in making patients and HCPs aware of forthcoming trials?
• How can existing relationships with advocacy groups and patients create a long-term pipeline of informed patients willing to take part in trials?
• Deliver clinical trial patient materials in digestible language to ensure patient understanding and informed consent and increase trial recruitment
Samira Diouane, Global Clinical Research Manager, Rare Diseases, Ipsen
NEXT-GEN DATA INNOVATIONS
15:10 Harness Gold-Standard Data Analytics To Drive Effective Data Collection & Application Of Trial Insights
• How can we balance anonymisation with accurate data to generate meaningful insights from trial data?
• Focus your data collection on the issues patients care about and collect the evidence that truly matters to them
• How can AI and data innovations rapidly speed up trial processes and drive next-level improvements in evidence gathering?
• Data security is never more important than with dealing with medical information, so how can we ensure patients feel secure about how their data is being handled and used?
DIVERSITY & INCLUSION IN CLINICAL TRIALS
15:30 Reach All Patient Populations & Build Inclusive Trial Processes That Power Patient Participation From Underrepresented Groups
• What effective methods can reduce mistrust in underrepresented groups and boost recruitment in key patient cohorts?
• How can diversity be built in as a priority of trial design to recruit a truly diverse and representative patient population?
• Evidence diverse trials ensure better drugs and treatments! Build the case and narrative to explain how broader patient population samples result in better results
• Digital innovations are crucial to improving diversity, but how can we ensure that new tech implementation is opening doors for patients, rather than closing them?
• What innovative channels can be harnessed to communicate with underrepresented populations and effectively engage them to participate in trials?
15.50 Afternoon Refreshment Break With Informal Networking
PAEDIATRIC CLINICAL TRIALS - CASE STUDY
16:20 All Patients Deserve The Right To Have An Active Role In Research & To Contribute To Any Decision That Regards Their Health. Engaging Children & Young People In Clinical Research Requires Specific Considerations To Facilitate The Best And Meaningful Contribution Of The Paediatric Patients, & Also The Ethical And Methodological Considerations That Are Required. Training Young People To Have An Active Role In Clinical Research Is Essential, And In This Session We Will Discuss How To Educate Young People & How To Ensure Their Meaningful Involvement.
Begonya Nafria, Patient Engagement in Research Coordinator, Sant Joan de Déu Research Foundation
INTERNAL COLLABORATIONS & STAKEHOLDER ENGAGEMENT
16:40 Effectively Balance Complex Stakeholder Voices & Develop Meaningful Collaboration To Focus Actions On Patient & Trial Outcomes
• Align complex stakeholder voices around the key issues that demonstrably boost patient experiences during trials and retain them throughout the clinical process
• How can innovative trial evidence be effectively communicated to stakeholders such as HCPs and payers to get them on board?
• Patients can frequently get lost in the mix of other stakeholders, so how can we ensure their voice is heard at the same volume and ensure they’re an equal partner in trial design processes?
Regine Buffels, Principal Global Medical Affairs Director, Roche
FUTURE-PROOFED CLINICAL TRIALS - Q&A PANEL
17:00 Ensure Future Success & Evolve Clinical Trials Post-Pandemic To Ensure Long-Term Clinical Success & Regulatory Approval
• The pandemic has brought a huge number of changes to the way clinical trials operate, but which of these are here to stay and which will be a flash in the pan?
• As genomic sequencing assists in segmenting patient cohorts more specifically, how can we ensure effective recruitment in trials when faced with smaller and smaller patient pools?
• How can clinical operations effectively keep pace with fast-moving and varying regulatory updates across multiple countries and regions?
Anne Ghent, Director Global R&D Compliance & Audit, Amgen
Andrew Foxley, VP R&D Franchise Head, Late Development Oncology, AstraZeneca
17.30 Official Close Of Conference
Take A Look At Our Upcoming Sister Events:
